Bullisch
$100.19
Szenariopreis
$75.230
+3.039 (+4.04%)Zum Schluss
DocuSign, Inc. provides intelligent agreement management (IAM) platform an eSignature solution, and contract lifecycle management (CLM) solution - allow organizations to increase productivity, accelerate contract review cycles, and transform agreement data into insights and actions. The Company’s IAM platform automates agreement workflows, uncovers actionable insights, and leverages artificial intelligence (AI) capabilities, enabling organizations to create, commit, and manage agreements virtually. Its products include eSignature, CLM, IAM Apps, and Add-on Products. Its Add-on Products include Payments to collect payments along with signed agreements; Identity and standards-based signature for enhanced signer-identification and signatures with digital certification; Notary for remote online notarization; Monitor for advanced analytics; Gen for Salesforce for automated agreement generation within Salesforce, among others.
DocuSign is currently priced at $71.08, with a forward P/E ratio of 15.13, suggesting it is reasonably valued compared to its earnings growth potential. However, the recent insider selling, with a 161.71% increase in selling activity, raises concerns about management's confidence in the stock's future performance. Additionally, the stock has only shown a 2.35% increase over the past year, indicating weak demand and potential risks in long-term commitments from customers. Given these factors, it may be prudent to hold rather than buy at this time.
BofA
$64
2026-09-04
BofA
2026-09-04
Kursziel
$64
UBS
$70
2026-09-04
UBS
2026-09-04
Kursziel
$70
RBC Capital
$70
2026-09-04
RBC Capital
2026-09-04
Kursziel
$70
Morgan Stanley
$75
2026-09-04
Morgan Stanley
2026-09-04
Kursziel
$75
Citi
$72
2026-09-04
Citi
2026-09-04
Kursziel
$72
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

Docusign Expands Partnership with Salesforce to Enhance Agreement Management

Docusign Executive Liquidates Shares Amid Growth

Docusign Executive Sells Shares Under Rule 10b5-1 Plan

Investment Analysis and Outlook on Software Stocks

Dreamforce 2026: Rising Debate on AI Safety
DocuSign, Inc. provides intelligent agreement management (IAM) platform an eSignature solution, and contract lifecycle management (CLM) solution - allow organizations to increase productivity, accelerate contract review cycles, and transform agreement data into insights and actions. The Company’s IAM platform automates agreement workflows, uncovers actionable insights, and leverages artificial intelligence (AI) capabilities, enabling organizations to create, commit, and manage agreements virtually. Its products include eSignature, CLM, IAM Apps, and Add-on Products. Its Add-on Products include Payments to collect payments along with signed agreements; Identity and standards-based signature for enhanced signer-identification and signatures with digital certification; Notary for remote online notarization; Monitor for advanced analytics; Gen for Salesforce for automated agreement generation within Salesforce, among others. It operates in the Technology sector (SERVICES-PREPACKAGED SOFTWARE industry).
DocuSign is currently priced at $71.08, with a forward P/E ratio of 15.13, suggesting it is reasonably valued compared to its earnings growth potential. However, the recent insider selling, with a 161.71% increase in selling activity, raises concerns about management's confidence in the stock's future performance. Additionally, the stock has only shown a 2.35% increase over the past year, indicating weak demand and potential risks in long-term commitments from customers. Given these factors, it may be prudent to hold rather than buy at this time.
8 analysts cover DOCU: 5 rate it Buy, 3 Hold and 0 Sell. The average price target is 80.23.

$DOCU DocuSign price target raised to $60 from $55 at Wells Fargo Wells Fargo analyst Michael Turrin raised the firm's price target on DocuSign to $60 from $55 and keeps an Equal Weight rating on the shares. The firm notes DocuSign's Q2 was "relatively down the middle." Wells expects investor questions around normalized growth rates, IAM uplift and FY28 trajectory will persist.
Mehr anzeigenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.